Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 789

1.

Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study.

Rini BI, Pal SK, Escudier BJ, Atkins MB, Hutson TE, Porta C, Verzoni E, Needle MN, McDermott DF.

Lancet Oncol. 2019 Dec 3. pii: S1470-2045(19)30735-1. doi: 10.1016/S1470-2045(19)30735-1. [Epub ahead of print]

PMID:
31810797
2.

Analysis of Heterogeneity in Survival Benefit of Immunotherapy in Oncology According to Patient Demographics and Performance Status: A Systematic Review and Meta-Analysis of Overall Survival Data.

Butaney M, Satkunasivam R, Goldberg H, Freedland SJ, Patel SP, Hamid O, Pal SK, Klaassen Z, Wallis CJD.

Am J Clin Oncol. 2019 Dec 4. doi: 10.1097/COC.0000000000000650. [Epub ahead of print]

PMID:
31809328
3.

Targeted therapies for advanced bladder cancer: new strategies with FGFR inhibitors.

Casadei C, Dizman N, Schepisi G, Cursano MC, Basso U, Santini D, Pal SK, De Giorgi U.

Ther Adv Med Oncol. 2019 Nov 25;11:1758835919890285. doi: 10.1177/1758835919890285. eCollection 2019. Review.

PMID:
31803255
4.

Cabozantinib in Combination with Immunotherapy for Advanced Renal Cell Carcinoma and Urothelial Carcinoma: Rationale and Clinical Evidence.

Bergerot P, Lamb P, Wang E, Pal SK.

Mol Cancer Ther. 2019 Dec;18(12):2185-2193. doi: 10.1158/1535-7163.MCT-18-1399. Review.

PMID:
31792125
5.

Precision Oncology for Hepatocellular Cancer: Slivering the Liver by FGF19-FGF4-KLB Pathway Inhibition.

Subbiah V, Pal SK.

Cancer Discov. 2019 Dec;9(12):1646-1649. doi: 10.1158/2159-8290.CD-19-1156.

PMID:
31792121
6.

Spectroscopy of an intrinsic fluorophore in animal and plant milk for potential identification of their quality.

Roy L, Halder A, Singh S, Patwari J, Singh P, Bhattacharya K, Mondal S, Pal SK.

J Dairy Sci. 2019 Nov 27. pii: S0022-0302(19)31052-5. doi: 10.3168/jds.2019-17034. [Epub ahead of print]

PMID:
31785872
7.

Peroxisome proliferator-activated receptor gamma controls prostate cancer cell growth through AR-dependent and independent mechanisms.

Elix CC, Salgia MM, Otto-Duessel M, Copeland BT, Yoo C, Lee M, Tew BY, Ann D, Pal SK, Jones JO.

Prostate. 2019 Nov 26. doi: 10.1002/pros.23928. [Epub ahead of print]

PMID:
31769890
8.

Distress and Quality of Life Among Patients with Advanced Genitourinary Cancers.

Bergerot CD, Philip EJ, Bergerot PG, Pal SK.

Eur Urol Focus. 2019 Nov 8. pii: S2405-4569(19)30336-0. doi: 10.1016/j.euf.2019.10.014. [Epub ahead of print]

PMID:
31711933
9.

High Hole Mobility and Efficient Ambipolar Charge Transport in Heterocoronene-Based Ordered Columnar Discotics.

De J, Bala I, Gupta SP, Pandey UK, Pal SK.

J Am Chem Soc. 2019 Nov 27;141(47):18799-18805. doi: 10.1021/jacs.9b09126. Epub 2019 Nov 13.

PMID:
31682432
10.

Potential Roles for PD-1 Inhibition and Cabozantinib in Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma.

Hahn AW, Pal SK, Agarwal N.

Oncologist. 2019 Oct 15. pii: theoncologist.2019-0657. doi: 10.1634/theoncologist.2019-0657. [Epub ahead of print] No abstract available.

PMID:
31615950
11.

The Pan-Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA.

Disel U, Madison R, Abhishek K, Chung JH, Trabucco SE, Matos AO, Frampton GM, Albacker LA, Reddy V, Karadurmus N, Benson A, Webster J, Paydas S, Cabanillas R, Nangia C, Ozturk MA, Millis SZ, Pal SK, Wilky B, Sokol ES, Gay LM, Soman S, Ganesan S, Janeway K, Stephens PJ, Zhu VW, Ou SI, Lovly CM, Gounder M, Schrock AB, Ross JS, Miller VA, Klempner SJ, Ali SM.

Oncologist. 2019 Oct 11. pii: theoncologist.2018-0528. doi: 10.1634/theoncologist.2018-0528. [Epub ahead of print]

PMID:
31604903
12.

First-Line Systemic Therapy for Metastatic Clear-Cell Renal Cell Carcinoma: Critical Appraisal of Emerging Options.

Loo V, Salgia M, Bergerot P, Philip EJ, Pal SK.

Target Oncol. 2019 Dec;14(6):639-645. doi: 10.1007/s11523-019-00676-y. Review.

PMID:
31595385
13.

First-line Treatment of Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.

Hahn AW, Klaassen Z, Agarwal N, Haaland B, Esther J, Ye XY, Wang X, Pal SK, Wallis CJD.

Eur Urol Oncol. 2019 Nov;2(6):708-715. doi: 10.1016/j.euo.2019.09.002. Epub 2019 Oct 4. Review.

PMID:
31588018
14.

Manganese neurotoxicity: nano-oxide compensates for ion-damage in mammals.

Adhikari A, Das M, Mondal S, Darbar S, Das AK, Bhattacharya SS, Pal D, Pal SK.

Biomater Sci. 2019 Nov 1;7(11):4491-4502. doi: 10.1039/c9bm01039d. Epub 2019 Sep 30.

PMID:
31566646
15.

An Access to Androgen Excess: The Ovary Unregulated.

Agrawal N, Datta S, Chakrabarty P, Arora V, Pal SK.

J Assoc Physicians India. 2019 Aug;67(8):87-88.

PMID:
31562730
16.

Factors that influence the androgen receptor cistrome in benign and malignant prostate cells.

Copeland BT, Du J, Pal SK, Jones JO.

Mol Oncol. 2019 Dec;13(12):2616-2632. doi: 10.1002/1878-0261.12572. Epub 2019 Oct 13.

17.

Polar Switching and Cybotactic Nematic Ordering in 1,3,4-Thiadiazole-Based Short-Core Hockey Stick-Shaped Fluorescent Liquid Crystals.

Saha SK, Mohiuddin G, Paul MK, Gupta SP, Khan RK, Ghosh S, Pal SK.

ACS Omega. 2019 Apr 26;4(4):7711-7722. doi: 10.1021/acsomega.9b00425. eCollection 2019 Apr 30.

18.

First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium.

Dudani S, Graham J, Wells JC, Bakouny Z, Pal SK, Dizman N, Donskov F, Porta C, de Velasco G, Hansen A, Iafolla M, Beuselinck B, Vaishampayan UN, Wood LA, Liow E, Yan F, Yuasa T, Bjarnason GA, Choueiri TK, Heng DYC.

Eur Urol. 2019 Dec;76(6):861-867. doi: 10.1016/j.eururo.2019.07.048. Epub 2019 Aug 22.

PMID:
31445844
19.

Non-invasive diagnosis and monitoring of urothelial bladder cancer: are we there yet?

Jain RK, Grivas P, Pal SK.

BJU Int. 2019 Sep;124(3):361-362. doi: 10.1111/bju.14877. No abstract available.

PMID:
31436040
20.

Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study.

Ornstein MC, Pal SK, Wood LS, Tomer JM, Hobbs BP, Jia XS, Allman KD, Martin A, Olencki T, Davis NB, Gilligan TD, Mortazavi A, Rathmell WK, Garcia JA, Rini BI.

Lancet Oncol. 2019 Oct;20(10):1386-1394. doi: 10.1016/S1470-2045(19)30513-3. Epub 2019 Aug 16.

PMID:
31427205
21.

Cytoreductive Nephrectomy in Metastatic Papillary Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.

Graham J, Wells JC, Donskov F, Lee JL, Fraccon A, Pasini F, Porta C, Bowman IA, Bjarnason GA, Ernst DS, Rha SY, Beuselinck B, Hansen A, North SA, Kollmannsberger CK, Wood LA, Vaishampayan UN, Pal SK, Choueiri TK, Heng DYC.

Eur Urol Oncol. 2019 Nov;2(6):643-648. doi: 10.1016/j.euo.2019.03.007. Epub 2019 Apr 5.

PMID:
31411994
22.

Incidence, Patterns, and Outcomes with Adjuvant Chemotherapy for Residual Disease After Neoadjuvant Chemotherapy in Muscle-invasive Urinary Tract Cancers.

Martinez Chanza N, Werner L, Plimack E, Yu EY, Alva AS, Crabb SJ, Powles T, Rosenberg JE, Baniel J, Vaishampayan UN, Berthold DR, Ladoire S, Hussain SA, Milowsky MI, Agarwal N, Necchi A, Pal SK, Sternberg CN, Bellmunt J, Galsky MD, Harshman LC; RISC Investigators.

Eur Urol Oncol. 2019 Jan 30. pii: S2588-9311(19)30001-X. doi: 10.1016/j.euo.2018.12.013. [Epub ahead of print]

PMID:
31411990
23.

Improvement of Photostability and NIR Activity of Cyanine Dye through Nanohybrid Formation: Key Information from Ultrafast Dynamical Studies.

Bera A, Bagchi D, Pal SK.

J Phys Chem A. 2019 Aug 22. doi: 10.1021/acs.jpca.9b04100. [Epub ahead of print]

PMID:
31402654
24.

Patterns of treatment in metastatic renal cell carcinoma for older versus younger patients.

Hahn AW, Esther J, Haaland B, Swami U, Dizman N, Rathi N, Maughan BL, Pal SK, Agarwal N.

J Geriatr Oncol. 2019 Aug 8. pii: S1879-4068(19)30128-6. doi: 10.1016/j.jgo.2019.07.002. [Epub ahead of print] No abstract available.

PMID:
31402176
25.

Association between chemotherapy toxicity risk scores and physical symptoms among older Brazilian adults with cancer.

Bergerot CD, Razavi M, Philip EJ, Bergerot PG, Soto-Perez-de-Celis E, De Domenico EBL, Clark KL, Loscalzo M, Pal SK, Dale W.

J Geriatr Oncol. 2019 Aug 8. pii: S1879-4068(19)30191-2. doi: 10.1016/j.jgo.2019.07.006. [Epub ahead of print]

PMID:
31401205
26.

Identifying Drug Resistant miRNAs using Entropy Based Ranking.

Pal JK, Ray SS, Pal SK.

IEEE/ACM Trans Comput Biol Bioinform. 2019 Aug 6. doi: 10.1109/TCBB.2019.2933205. [Epub ahead of print]

PMID:
31398129
27.

Association Between Smoking and Survival Benefit of Immunotherapy in Advanced Malignancies: A Systematic Review and Meta-Analysis.

Wallis CJD, Satkunasivam R, Butaney M, Khan UA, Goldberg HA, Freedland SJ, Patel SP, Hamid O, Pal SK, Klaassen Z.

Am J Clin Oncol. 2019 Sep;42(9):711-716. doi: 10.1097/COC.0000000000000577.

PMID:
31335350
28.

Correction to "Liquid Crystal based Detection of Pb(II) Ions Using Spinach RNA as Recognition Probe".

Verma I, Devi M, Sharma D, Nandi R, Pal SK.

Langmuir. 2019 Jul 30;35(30):9994. doi: 10.1021/acs.langmuir.9b02053. Epub 2019 Jul 19. No abstract available.

PMID:
31322354
29.

Different roles of peroxisome proliferator-activated receptor gamma isoforms in prostate cancer.

Salgia MM, Elix CC, Pal SK, Jones JO.

Am J Clin Exp Urol. 2019 Jun 15;7(3):98-109. eCollection 2019.

30.

Characterizing the Wnt Pathway in Advanced Prostate Cancer: When, Why, and How.

Pal SK, Swami U, Agarwal N.

Eur Urol. 2019 Jul 9. pii: S0302-2838(19)30519-6. doi: 10.1016/j.eururo.2019.06.029. [Epub ahead of print] No abstract available.

PMID:
31300236
31.

Ideal Glucocorticoid Regimen With Abiraterone Acetate: Options and Challenges.

Swami U, Pal SK, Agarwal N.

JAMA Oncol. 2019 Jun 27. doi: 10.1001/jamaoncol.2019.1008. [Epub ahead of print] No abstract available.

PMID:
31246246
32.

Prospective Comprehensive Genomic Profiling of Primary and Metastatic Prostate Tumors.

Chung JH, Dewal N, Sokol E, Mathew P, Whitehead R, Millis SZ, Frampton GM, Bratslavsky G, Pal SK, Lee RJ, Necchi A, Gregg JP, Lara P Jr, Antonarakis ES, Miller VA, Ross JS, Ali SM, Agarwal N.

JCO Precis Oncol. 2019;3. doi: 10.1200/PO.18.00283. Epub 2019 May 10.

33.

Tumor downstaging as an intermediate endpoint to assess the activity of neoadjuvant systemic therapy in patients with muscle-invasive bladder cancer.

Martini A, Jia R, Ferket BS, Waingankar N, Plimack ER, Crabb SJ, Harshman LC, Yu EY, Powles T, Rosenberg JE, Pal SK, Vaishampayan UN, Necchi A, Wiklund NP, Mehrazin R, Mazumdar M, Sfakianos JP, Galsky MD.

Cancer. 2019 Sep 15;125(18):3155-3163. doi: 10.1002/cncr.32169. Epub 2019 May 31.

34.

Liquid Crystal based Detection of Pb(II) Ions Using Spinach RNA as Recognition Probe.

Verma I, Devi M, Sharma D, Nandi R, Pal SK.

Langmuir. 2019 Jun 18;35(24):7816-7823. doi: 10.1021/acs.langmuir.8b04018. Epub 2019 May 30. Erratum in: Langmuir. 2019 Jul 30;35(30):9994.

PMID:
31117720
35.

Individualised Indications for Cytoreductive Nephrectomy: Which Criteria Define the Optimal Candidates?

Larcher A, Wallis CJD, Bex A, Blute ML, Ficarra V, Mejean A, Karam JA, Van Poppel H, Pal SK.

Eur Urol Oncol. 2019 Jul;2(4):365-378. doi: 10.1016/j.euo.2019.04.007. Epub 2019 May 18. Review.

PMID:
31109902
36.

Exciton dissociation in an NIR-active triohybrid nanocrystal leading to efficient generation of reactive oxygen species.

Patwari J, Joshi H, Mandal H, Roy L, Bhattacharya C, Lemmens P, Pal SK.

Phys Chem Chem Phys. 2019 May 28;21(20):10667-10676. doi: 10.1039/c9cp01923e. Epub 2019 May 14.

PMID:
31086863
37.

Modulation of Kinetic Pathways of Enzyme-Substrate Interaction in a Microfluidic Channel: Nanoscopic Water Dynamics as a Switch.

Singh P, Mukherjee D, Singha S, Das R, Pal SK.

Chemistry. 2019 Jul 22;25(41):9728-9736. doi: 10.1002/chem.201901751. Epub 2019 Jun 28.

PMID:
31062438
38.

Generation of orthogonal lattice fields.

Pal SK, Senthilkumaran P.

J Opt Soc Am A Opt Image Sci Vis. 2019 May 1;36(5):853-858. doi: 10.1364/JOSAA.36.000853.

PMID:
31045013
39.

In situ measurement of temperature dependent picosecond resolved carrier dynamics in near infrared (NIR) sensitive device on action.

Patwari J, Chatterjee A, Ghadi H, Sharma H, Chakrabarti S, Pal SK.

Rev Sci Instrum. 2019 Apr;90(4):043909. doi: 10.1063/1.5050951.

PMID:
31042972
40.

Structural Understanding, Photoswitchability, and Supergelation of a New Class of Four Ring-Based Bent-Shaped Liquid Crystal.

Begum N, Kaur S, Mohiuddin G, Nandi R, Gupta SP, Rao NVS, Pal SK.

J Phys Chem B. 2019 May 23;123(20):4443-4451. doi: 10.1021/acs.jpcb.9b01456. Epub 2019 May 10.

PMID:
31042387
41.

Reduced T-cell Numbers and Elevated Levels of Immunomodulatory Cytokines in Metastatic Prostate Cancer Patients De Novo Resistant to Abiraterone and/or Enzalutamide Therapy.

Pal SK, Moreira D, Won H, White SW, Duttagupta P, Lucia M, Jones J, Hsu J, Kortylewski M.

Int J Mol Sci. 2019 Apr 13;20(8). pii: E1831. doi: 10.3390/ijms20081831.

42.

Hexagonal vector field of polarization singularities with a gradient basis structure.

Pal SK, Senthilkumaran P.

Opt Lett. 2019 Apr 15;44(8):2093-2096. doi: 10.1364/OL.44.002093.

PMID:
30985819
43.

Effectiveness and Safety of Metformin versus Canthex™ in Patients with Acanthosis Nigricans: A Randomized, Double-blind Controlled Trial.

Sett A, Pradhan S, Sancheti K, Basu D, Datta A, Biswas L, Das S, Pal SK, Gupta N, Sil A, Das NK.

Indian J Dermatol. 2019 Mar-Apr;64(2):115-121. doi: 10.4103/ijd.IJD_417_17.

44.

The Changing Landscape of Management of Metastatic Renal Cell Carcinoma: Current Treatment Options and Future Directions.

Salgia NJ, Dara Y, Bergerot P, Salgia M, Pal SK.

Curr Treat Options Oncol. 2019 Apr 1;20(5):41. doi: 10.1007/s11864-019-0638-1. Review.

PMID:
30937639
45.

Postsynthesis Spontaneous Coalescence of Mixed-Halide Perovskite Nanocubes into Phase-Stable Single-Crystalline Uniform Luminescent Nanowires.

Pradhan B, Mushtaq A, Roy D, Sain S, Das B, Ghorai UK, Pal SK, Acharya S.

J Phys Chem Lett. 2019 Apr 18;10(8):1805-1812. doi: 10.1021/acs.jpclett.9b00832. Epub 2019 Apr 2.

PMID:
30929427
47.

Mechanistic Investigation of the Androgen Receptor DNA-Binding Domain Inhibitor Pyrvinium.

Pal SK, Tew BY, Lim M, Stankavich B, He M, Pufall M, Hu W, Chen Y, Jones JO.

ACS Omega. 2019 Feb 28;4(2):2472-2481. doi: 10.1021/acsomega.8b03205. Epub 2019 Feb 1.

48.

Perception of cure among patients with metastatic genitourinary cancer initiating immunotherapy.

Bergerot CD, Bergerot PG, Philip EJ, Hsu JA, Dizman N, Vaishampayan U, Dorff T, Pal SK.

J Immunother Cancer. 2019 Mar 12;7(1):71. doi: 10.1186/s40425-019-0557-5.

49.

Examining Public Communication About Kidney Cancer on Twitter.

Sedrak MS, Salgia MM, Decat Bergerot C, Ashing-Giwa K, Cotta BN, Adashek JJ, Dizman N, Wong AR, Pal SK, Bergerot PG.

JCO Clin Cancer Inform. 2019 Mar;3:1-6. doi: 10.1200/CCI.18.00088.

50.

Patient-reported Outcome Measures in Metastatic Urinary Cancers.

Bergerot CD, Bergerot PG, Philip EJ, Pal SK.

Eur Urol Focus. 2019 Mar 8. pii: S2405-4569(19)30055-0. doi: 10.1016/j.euf.2019.02.020. [Epub ahead of print] Review.

PMID:
30858072

Supplemental Content

Support Center